FGF23 and X-linked hypophosphatemia: Through optimization of the delivery platform, we demonstrated that treatment with AAV-cFGF23 inhibited FGF23 signaling in kidney, resulting in increased expression of the Npt2a transporter and complete rescue of bone mineralization and osteomalacia in a mouse model of XLH.